Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice

Nurul Elyani Mohamad, Nadiah Abu, Heshu Sulaiman Rahman, Huynh Ky, Wan Yong Ho, Kian Lam Lim, Chee Wun How, Abdullah Rasedee, Noorjahan Banu Alitheen, Swee Keong Yeap

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Zerumbone is a potential anti-inflammatory, immunomodulatory and anti-tumor agent. However, the major problems that prevent the in vivo and even clinical applications of Zerumbone are its water insolubility that compromises its bioavailability. To enhance the bioavailability and efficacy of Zerumbone, nanostructured lipid carriers (NLC) were used to encapsulate Zerumbone. NLC-Zerumbone has been reported to have a slow release, comparable in vitro cytotoxicity against leukemia and breast cancer, and no observed in vivo oral acute toxicity. However, the in vivo antitumor effect of NLC-Zerumbone is still unknown. The anti-tumor, immunostimulatory and anti-inflammatory effects of Zerumbone and NLC-Zerumbone in 4T1 challenged mice were compared in this study. Zerumbone effectively controlled the tumor growth and metastasis via delaying the cancer cell cycle progression and apoptosis. Besides, Zerumbone also enhanced the anti-tumor immunity and anti-inflammatory effects. NLC encapsulation was found to further improve the anti-tumor, immunomodulation, anti-inflammation and anti-metastatic efficacy of Zerumbone in 4T1 challenged mice. This study provides the possibility of utilizing NLC encapsulated Zerumbone for breast cancer therapy.

Original languageEnglish
Pages (from-to)22066-22074
Number of pages9
JournalRSC Advances
Volume5
Issue number28
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Lipids
Tumors
Anti-Inflammatory Agents
Cell death
Cytotoxicity
Encapsulation
Toxicity
zerumbone
Solubility
Cells
Water
Apoptosis
Biological Availability

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice. / Mohamad, Nurul Elyani; Abu, Nadiah; Rahman, Heshu Sulaiman; Ky, Huynh; Ho, Wan Yong; Lim, Kian Lam; How, Chee Wun; Rasedee, Abdullah; Alitheen, Noorjahan Banu; Yeap, Swee Keong.

In: RSC Advances, Vol. 5, No. 28, 01.01.2015, p. 22066-22074.

Research output: Contribution to journalArticle

Mohamad, NE, Abu, N, Rahman, HS, Ky, H, Ho, WY, Lim, KL, How, CW, Rasedee, A, Alitheen, NB & Yeap, SK 2015, 'Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice', RSC Advances, vol. 5, no. 28, pp. 22066-22074. https://doi.org/10.1039/c5ra00144g
Mohamad, Nurul Elyani ; Abu, Nadiah ; Rahman, Heshu Sulaiman ; Ky, Huynh ; Ho, Wan Yong ; Lim, Kian Lam ; How, Chee Wun ; Rasedee, Abdullah ; Alitheen, Noorjahan Banu ; Yeap, Swee Keong. / Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice. In: RSC Advances. 2015 ; Vol. 5, No. 28. pp. 22066-22074.
@article{99ab9273aa434f08b3c4e1e1054f0ff5,
title = "Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice",
abstract = "Zerumbone is a potential anti-inflammatory, immunomodulatory and anti-tumor agent. However, the major problems that prevent the in vivo and even clinical applications of Zerumbone are its water insolubility that compromises its bioavailability. To enhance the bioavailability and efficacy of Zerumbone, nanostructured lipid carriers (NLC) were used to encapsulate Zerumbone. NLC-Zerumbone has been reported to have a slow release, comparable in vitro cytotoxicity against leukemia and breast cancer, and no observed in vivo oral acute toxicity. However, the in vivo antitumor effect of NLC-Zerumbone is still unknown. The anti-tumor, immunostimulatory and anti-inflammatory effects of Zerumbone and NLC-Zerumbone in 4T1 challenged mice were compared in this study. Zerumbone effectively controlled the tumor growth and metastasis via delaying the cancer cell cycle progression and apoptosis. Besides, Zerumbone also enhanced the anti-tumor immunity and anti-inflammatory effects. NLC encapsulation was found to further improve the anti-tumor, immunomodulation, anti-inflammation and anti-metastatic efficacy of Zerumbone in 4T1 challenged mice. This study provides the possibility of utilizing NLC encapsulated Zerumbone for breast cancer therapy.",
author = "Mohamad, {Nurul Elyani} and Nadiah Abu and Rahman, {Heshu Sulaiman} and Huynh Ky and Ho, {Wan Yong} and Lim, {Kian Lam} and How, {Chee Wun} and Abdullah Rasedee and Alitheen, {Noorjahan Banu} and Yeap, {Swee Keong}",
year = "2015",
month = "1",
day = "1",
doi = "10.1039/c5ra00144g",
language = "English",
volume = "5",
pages = "22066--22074",
journal = "RSC Advances",
issn = "2046-2069",
publisher = "Royal Society of Chemistry",
number = "28",

}

TY - JOUR

T1 - Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice

AU - Mohamad, Nurul Elyani

AU - Abu, Nadiah

AU - Rahman, Heshu Sulaiman

AU - Ky, Huynh

AU - Ho, Wan Yong

AU - Lim, Kian Lam

AU - How, Chee Wun

AU - Rasedee, Abdullah

AU - Alitheen, Noorjahan Banu

AU - Yeap, Swee Keong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Zerumbone is a potential anti-inflammatory, immunomodulatory and anti-tumor agent. However, the major problems that prevent the in vivo and even clinical applications of Zerumbone are its water insolubility that compromises its bioavailability. To enhance the bioavailability and efficacy of Zerumbone, nanostructured lipid carriers (NLC) were used to encapsulate Zerumbone. NLC-Zerumbone has been reported to have a slow release, comparable in vitro cytotoxicity against leukemia and breast cancer, and no observed in vivo oral acute toxicity. However, the in vivo antitumor effect of NLC-Zerumbone is still unknown. The anti-tumor, immunostimulatory and anti-inflammatory effects of Zerumbone and NLC-Zerumbone in 4T1 challenged mice were compared in this study. Zerumbone effectively controlled the tumor growth and metastasis via delaying the cancer cell cycle progression and apoptosis. Besides, Zerumbone also enhanced the anti-tumor immunity and anti-inflammatory effects. NLC encapsulation was found to further improve the anti-tumor, immunomodulation, anti-inflammation and anti-metastatic efficacy of Zerumbone in 4T1 challenged mice. This study provides the possibility of utilizing NLC encapsulated Zerumbone for breast cancer therapy.

AB - Zerumbone is a potential anti-inflammatory, immunomodulatory and anti-tumor agent. However, the major problems that prevent the in vivo and even clinical applications of Zerumbone are its water insolubility that compromises its bioavailability. To enhance the bioavailability and efficacy of Zerumbone, nanostructured lipid carriers (NLC) were used to encapsulate Zerumbone. NLC-Zerumbone has been reported to have a slow release, comparable in vitro cytotoxicity against leukemia and breast cancer, and no observed in vivo oral acute toxicity. However, the in vivo antitumor effect of NLC-Zerumbone is still unknown. The anti-tumor, immunostimulatory and anti-inflammatory effects of Zerumbone and NLC-Zerumbone in 4T1 challenged mice were compared in this study. Zerumbone effectively controlled the tumor growth and metastasis via delaying the cancer cell cycle progression and apoptosis. Besides, Zerumbone also enhanced the anti-tumor immunity and anti-inflammatory effects. NLC encapsulation was found to further improve the anti-tumor, immunomodulation, anti-inflammation and anti-metastatic efficacy of Zerumbone in 4T1 challenged mice. This study provides the possibility of utilizing NLC encapsulated Zerumbone for breast cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84923887182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923887182&partnerID=8YFLogxK

U2 - 10.1039/c5ra00144g

DO - 10.1039/c5ra00144g

M3 - Article

VL - 5

SP - 22066

EP - 22074

JO - RSC Advances

JF - RSC Advances

SN - 2046-2069

IS - 28

ER -